Express Mail No. EV 641 736 666 US

INFORMATION	Attorney Docket	RICE-050	
DISCLOSURE STATEMENT	First Named Inventor	MACKAY, CHARLES REAY	
	Application Number	10/584,480	
	Confirmation No.	3065	
	Filing Date	Not yet assigned	
Address to: Mail Stop Box PCT	Group Art Unit	Not yet assigned	
Commissioner for Patents	Examiner Name	Not yet assigned	
P.O. Box 1450 Alexandria, VA 22313-1450	COMPRISING	IC NON-HUMAN MAMMAL G A POLYNUCLEOTIDE ENCODING HUMANIZED C5AR"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RICE-050 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

BOZICEVIC, FIELD & FRANCIS LLP

1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\RICE\050\First IDS filed with Miss Req.doc

By:

Carol L. Francis, Ph.D.

Registration V6. 36,513

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/584,480	
l				Filing Date	Not yet assigned	
ļ				First Named Inventor	MACKAY, CHARLES REAY	
				Art Unit	Not yet assigned	
(Use as many sheets as necessary)			ny)	Examiner Name	Not yet assigned	
Sheet	1	of	2	Attorney Docket Number	RICE-050	

			U.S. PATENT I	DOCUMENTS	
Examiner Initials'	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-		·	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵		
		WO 98/24893	06/11/1998	Abgenix, Inc.				
		WO 94/20142	09/15/;1994	Center for Blood Research, Inc.	_			
		WO 95/00164	01/05/1995	The Scripps Research Institute				

Examiner	Da	ate	
Signature	Co	onsidered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/584,480	
INFORMATION DISCLOSURE				Filing Date	Not yet assigned	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	MACKAY, CHARLES REAY	
			CANI	Art Unit	Not yet assigned	
			ny)	Examiner Name	Not yet assigned	
Sheet	2	of	2	Attorney Docket Number	RICE-050	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		Gerard, N. P. et al. Human chemotaxis receptor genes cluster at 19q13.3-13.4. characterization of the human C5a receptor gene. Biochemistry (1993), 32: 1243-1250.						
		Höpken, U.E. et al. The C5a chemoattractant receptor mediates mucosal defence to infection, Nature (1996), 383: 86-89.						
		Heller et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. The Journal of Immunology (1999) 163: 985-994.	:					
		Köhl, J. et al. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Molecular Immunology (2001) 38: 175-187.						
		Data						

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.